These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3673584)

  • 41. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model.
    Thieme L; Hartung A; Makarewicz O; Pletz MW
    J Antimicrob Chemother; 2020 Aug; 75(8):2173-2181. PubMed ID: 32357212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experimental pneumococcus infection in mice: comparative in vitro and in vivo effect of cefuroxime, cefotaxime and ceftriaxone.
    Frimodt-Møller N; Bentzon MW; Thomsen VF
    Acta Pathol Microbiol Immunol Scand B; 1987 Oct; 95(5):261-7. PubMed ID: 3673583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergism of ampicillin and gentamicin against obstructive pyelonephritis due to Escherichia coli in rats.
    Glauser MP; Lyons JM; Braude AI
    J Infect Dis; 1979 Feb; 139(2):133-40. PubMed ID: 374640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci.
    Chow JW; Donabedian SM; Clewell DB; Sahm DF; Zervos MJ
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):141-6. PubMed ID: 9884829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of beta-lactam antibiotics in the treatment of septicaemia and endocarditis.
    Watanakunakorn C
    Scand J Infect Dis Suppl; 1984; 42():110-6. PubMed ID: 6442009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
    Gavaldá J; Onrubia PL; Gómez MT; Gomis X; Ramírez JL; Len O; Rodríguez D; Crespo M; Ruíz I; Pahissa A
    J Antimicrob Chemother; 2003 Sep; 52(3):514-7. PubMed ID: 12917251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].
    Bogdanov MB; Chernen'kaia TV
    Antibiot Khimioter; 2000; 45(10):15-8. PubMed ID: 11212394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of combinations of selected antibiotics on the growth of Corynebacterium equi.
    Prescott JF; Nicholson VM
    J Vet Pharmacol Ther; 1984 Mar; 7(1):61-4. PubMed ID: 6561258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies.
    Serra P; Brandimarte C; Martino P; Carlone S; Giunchi G
    Arch Intern Med; 1977 Nov; 137(11):1562-7. PubMed ID: 921443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Penicillin-resistant Streptococcus pneumoniae: selection by both beta-lactam and non-beta-lactam antibiotics.
    Goldstein FW
    J Antimicrob Chemother; 1999 Aug; 44(2):141-4. PubMed ID: 10473219
    [No Abstract]   [Full Text] [Related]  

  • 52. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Protective effect of stem-bromelain in combination with antibiotics on experimental infection in mice induced by Streptococcus hemolyticus, Diplococcus pneumoniae, or Pseudomonas aeruginosa (author's transl)].
    Ishikawa H; Oguro Y
    Jpn J Antibiot; 1974 Apr; 27(2):118-21. PubMed ID: 4152712
    [No Abstract]   [Full Text] [Related]  

  • 54. In-vitro killing activity of combinations of beta-lactam agents with aminoglycosides against penicillin-resistant pneumococci.
    Schlegel L; Sissia G; Fremaux A; Geslin P
    J Antimicrob Chemother; 1997 Jan; 39(1):95-8. PubMed ID: 9044034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae.
    Brueggemann AB; Pfaller MA; Doern GV
    J Clin Microbiol; 2001 Jan; 39(1):367-9. PubMed ID: 11136803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Azithromycin compared with beta-lactam antibiotic treatment failures in pneumococcal infections of children.
    Gonzalez BE; Martinez-Aguilar G; Mason EO; Kaplan SL
    Pediatr Infect Dis J; 2004 May; 23(5):399-405. PubMed ID: 15131461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro assessment of CI-934--a new quinolone derivative.
    Finch R; Martin J; Pilkington R
    Chemioterapia; 1986 Dec; 5(6):368-74. PubMed ID: 3467873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enterococcus faecalis: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against high-level-gentamicin-resistant isolates.
    Traub WH; Leonhard B; Bauer D
    Chemotherapy; 1993; 39(4):248-53. PubMed ID: 8325126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial therapy of experimental group B streptococcal infection in mice.
    Deveikis A; Schauf V; Mizen M; Riff L
    Antimicrob Agents Chemother; 1977 May; 11(5):817-20. PubMed ID: 327920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolving clinical problems with Streptococcus pneumoniae: increasing resistance to antimicrobial agents, and failure of traditional optochin identification in Chicago, Illinois, between 1993 and 1996.
    Borek AP; Dressel DC; Hussong J; Peterson LR
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):209-14. PubMed ID: 9458976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.